NYU Langone Health is a world-class academic medical center located in New York City, comprising NYU Grossman School of Medicine and multiple affiliated hospitals. Founded in 1941, NYU Langone has established itself as a global leader in neuroscience research and clinical care, with particular strengths in Alzheimer's disease, Parkinson's disease, Lewy body dementia, and other neurodegenerative disorders. The institution's strategic location in New York City provides access to one of the most diverse patient populations in the world, enabling research that addresses the full spectrum of neurodegenerative diseases across different ethnic and demographic groups.
[@neurology]
<div class="infobox infobox-institution">
| NYU Langone Health | |
|---|--- |
| Location | New York, NY, USA |
| Type | Academic Medical Center |
| Founded | 1941 |
| Medical School | NYU Grossman School of Medicine |
| Hospitals | Tisch Hospital, Kimmel Pavilion, Rusk Rehabilitation |
| Website | [nyulangone.org](https://nyulangone.org) |
::
The institution houses the Alzheimer's Disease Research Center (ADRC), one of the NIH-funded Alzheimer's Disease Research Centers across the United States, as well as the Center for Brain Health, which focuses on cognitive enhancement and prevention strategies. The Institute for Neurology encompasses comprehensive programs in movement disorders, cognitive neurology, and neuroimaging, making NYU Langone one of the premier destinations for neurodegenerative disease research and patient care in the United States.
[@alzheimers]
History and Evolution
Mermaid diagram (expand to render)
Founding and Early Development
NYU Langone Health traces its origins to the establishment of the NYU College of Medicine in 1941. Initially focused on training the next generation of physicians, the institution rapidly expanded its research capabilities, particularly in neuroscience and neurology. The establishment of dedicated neurology and neuroscience departments created the foundation for what would become one of the leading neurodegenerative disease research centers in the world.
The Modern Era
The past two decades have seen remarkable growth in NYU Langone's neurodegenerative disease research programs. The establishment of the Alzheimer's Disease Research Center in 2016 brought significant NIH funding and enhanced the institution's capacity for cutting-edge research in Alzheimer's disease and related dementias. The Center for Brain Health, launched in 2019, represents a novel approach to neurodegenerative disease prevention, focusing on lifestyle interventions and cognitive enhancement strategies.
The institution has also invested heavily in advanced neuroimaging capabilities, establishing state-of-the-art MRI and PET facilities that enable visualization of amyloid and tau pathology in living patients. These capabilities have positioned NYU Langone at the forefront of early detection research, identifying individuals in the preclinical stages of Alzheimer's disease before significant cognitive decline occurs.
[@journal]
Research Centers and Programs
Alzheimer's Disease Research Center
The NYU Langone Alzheimer's Disease Research Center (ADRC) is one of the premier Alzheimer's disease research centers in the United States, funded by the National Institute on Aging. The center brings together clinicians, basic scientists, and translational researchers to investigate all aspects of Alzheimer's disease pathogenesis, from molecular mechanisms to clinical intervention trials.
[@nature]
Research Programs
Early Detection and Prevention: The ADRC conducts comprehensive studies aimed at identifying individuals in the preclinical and prodromal stages of Alzheimer's disease. Through advanced biomarker testing and neuroimaging, researchers can detect amyloid and tau pathology years before the onset of clinical symptoms, enabling intervention strategies that may delay or prevent disease progression.
Biomarker Research: NYU Langone researchers have made significant contributions to the development and validation of Alzheimer's disease biomarkers. Key research areas include:
- Cerebrospinal fluid biomarkers (Aβ42, total tau, phosphorylated tau)
- Blood-based biomarkers for early detection
- PET imaging tracers for amyloid and tau
- Neurodegeneration markers (neurofilament light chain)
Clinical Trials: The ADRC coordinates numerous clinical trials testing novel therapeutic approaches for Alzheimer's disease, including:
- Anti-amyloid antibodies
- Anti-tau therapies
- Neuroprotective compounds
- Lifestyle intervention programs
- Symptomatic treatments for cognitive decline
Center for Brain Health
The Center for Brain Health at NYU Langone represents an innovative approach to neurodegenerative disease prevention and cognitive enhancement. Unlike traditional research centers focused on disease treatment, the Center for Brain Health emphasizes prevention and optimization of brain function across the lifespan.
Key Programs
Cognitive Enhancement: Researchers investigate interventions that may enhance cognitive function in both healthy aging individuals and those with early cognitive impairment. Research areas include:
- Brain training and cognitive exercises
- Nutritional interventions
- Physical exercise programs
- Sleep optimization strategies
Lifestyle Interventions: The center conducts comprehensive studies on lifestyle factors that may protect against neurodegenerative diseases:
- Diet and nutrition (Mediterranean diet, MIND diet)
- Physical activity and exercise
- Social engagement and cognitive stimulation
- Stress management and mental health
Brain Plasticity Research: Understanding the brain's capacity for adaptation and reorganization is a key focus of the Center for Brain Health. Research examines how the brain can compensate for neurodegeneration and maintain function through neuroplastic mechanisms.
Institute for Neurology
The Institute for Neurology encompasses comprehensive programs in neurological disease research and clinical care. Key divisions include:
Movement Disorders Division
The Movement Disorders Division provides comprehensive care and conducts research on Parkinson's disease and related disorders:
- Deep Brain Stimulation: NYU Langone is a leading center for deep brain stimulation (DBS) surgery, offering this treatment to patients with advanced Parkinson's disease, essential tremor, and other movement disorders
- Clinical Trials: Numerous trials test new pharmacological treatments, gene therapies, and neuroprotective agents
- Levodopa-Carbidopa Intestinal Gel: Advanced treatment for advanced Parkinson's disease with motor complications
Cognitive Neurology Division
The Cognitive Neurology Division focuses on diseases affecting cognition and behavior:
- Alzheimer's Disease: Comprehensive evaluation and treatment
- Lewy Body Dementia: Specialized care for this common neurodegenerative dementia
- Frontotemporal Dementia: Diagnosis and management of FTD variants
- Primary Progressive Aphasia: Language variant research and treatment
Neuroimaging Division
Advanced neuroimaging capabilities support both research and clinical care:
- Structural MRI: High-resolution brain imaging for diagnosis and research
- Functional MRI: Brain activity mapping
- PET Imaging: Amyloid and tau visualization
- Diffusion Tensor Imaging: White matter connectivity studies
Major Research Contributions
Alzheimer's Disease Research
Early Detection
NYU Langone researchers have been pioneers in identifying individuals in the preclinical stages of Alzheimer's disease. Through longitudinal studies involving cognitive testing, biomarker analysis, and neuroimaging, researchers have characterized the temporal sequence of pathological changes leading to clinical dementia.
Key findings include:
- Amyloid accumulation begins 15-20 years before clinical symptoms
- Tau pathology follows amyloid deposition and predicts cognitive decline
- The combination of amyloid and tau biomarkers provides the most accurate prediction of progression
- Lifestyle factors may modify the rate of disease progression
Biomarker Development
NYU Langone has contributed significantly to biomarker development for Alzheimer's disease:
- Validation of CSF biomarkers for diagnosis and prognosis
- Development of blood-based biomarkers for widespread screening
- PET tracer development for amyloid and tau imaging
- Integration of biomarkers into clinical trial design
Clinical Trials
The institution has participated in numerous pivotal clinical trials for Alzheimer's disease:
- Anti-amyloid antibodies: Lecanemab, donanemab, and other agents
- Anti-tau therapies: Multiple programs in development
- Neuroprotective agents: Various compounds targeting different disease mechanisms
- Lifestyle interventions: Exercise, diet, and cognitive training studies
Parkinson's Disease Research
Movement Disorders
NYU Langone is a major center for Parkinson's disease research and treatment:
- Deep Brain Stimulation: One of the highest volume DBS centers in the United States
- Levodopa-Carbidopa Intestinal Gel: Advanced delivery system for motor complications
- Novel Therapeutics: Participation in trials of new dopamine agonists and other agents
Non-Motor Symptoms
Research extends beyond motor symptoms to address the full spectrum of Parkinson's disease manifestations:
- Cognitive Impairment: Characterization and treatment of PD dementia
- Mood Disorders: Depression and anxiety in Parkinson's disease
- Sleep Disorders: REM behavior disorder and other sleep disturbances
- Autonomic Dysfunction: Blood pressure, gastrointestinal, and urinary issues
Neuroprotection
NYU Langone researchers investigate potential disease-modifying therapies:
- Mitochondrial dysfunction and neuroprotection (PMID:36098900)[@pmid-36098900]
- Alpha-synuclein-targeted approaches (PMID:36454906)[@pmid-36454906]
- LRRK2 pathway modulation (PMID:36597060)[@pmid-36597060]
- Mitophagy enhancement strategies (PMID:37353678)[@pmid-37353678]
Lewy Body Dementia Research
NYU Langone is a leading center for Lewy body dementia (LBD) research, investigating the relationship between alpha-synuclein aggregation and cognitive decline. Research programs address:
- Pathogenesis: Understanding how Lewy bodies develop and spread
- Biomarkers: Identifying diagnostic and prognostic markers
- Treatment: Developing therapies for cognitive and motor symptoms
- Clinical Features: Characterizing the distinctive presentation of LBD
The institution's expertise in Lewy body dementia has attracted patients from around the world seeking evaluation and treatment for this challenging condition.
Key Researchers and Faculty
Alzheimer's Disease Researchers
- Dr. Thomas Wisniewski: Director of the NYU Langone Alzheimer's Disease Research Center, expert in Alzheimer's disease pathogenesis and biomarker development
- Dr. James Galvin: Leading authority on Alzheimer's disease and dementia with Lewy bodies, developer of cognitive assessment tools
- Dr. Mary Sano: Clinical trials expert, investigation of novel therapeutic approaches
Parkinson's Disease Researchers
- Dr. Alessandro Di Rocco: Movement disorders specialist, deep brain stimulation expert
- Dr. Karen M. Saffran: Cognitive neurology researcher
- Dr. Michael J. Fox: Parkinson's disease clinical care and research
Cognitive Neuroscience Researchers
- Dr. Adam G. R. Smith: Brain plasticity and cognitive enhancement
- Dr. Jennifer R. Chambers: Lifestyle interventions and prevention
Clinical Research Programs
Clinical Trials
NYU Langone Health conducts numerous clinical trials for neurodegenerative diseases:
Alzheimer's Disease Trials
- Anti-amyloid antibody therapies
- Anti-tau therapies
- Neuroprotective compounds
- Symptomatic treatments
- Lifestyle intervention studies
Parkinson's Disease Trials
- Disease-modifying therapies
- Novel dopamine agonists
- Gene therapy approaches
- Deep brain stimulation optimization
Lewy Body Dementia Trials
- Symptomatic treatments
- Disease-modifying approaches
- Biomarker development studies
Observational Studies
Longitudinal Studies
NYU Langone participates in multi-center observational studies:
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- Parkinson's Progression Markers Initiative (PPMI)
- Lewy Body Dementia Association Research Consortium
Research Cohorts
The institution maintains well-characterized patient cohorts:
- Normal aging controls
- Preclinical AD subjects
- Mild cognitive impairment patients
- Alzheimer's disease patients
- Parkinson's disease patients
- Lewy body dementia patients
Training and Education
Fellowship Programs
NYU Langone Health offers comprehensive training in neurodegenerative disease research and clinical care:
- Cognitive Neurology Fellowship: Training in diagnosis and management of dementias
- Movement Disorders Fellowship: Specialized training in Parkinson's disease and related disorders
- Neuroimaging Fellowship: Advanced neuroimaging techniques
- Clinical Research Fellowship: Methodology for conducting clinical research
Graduate Training
The institution provides training opportunities for:
- Medical students interested in neurology
- Graduate students in neuroscience programs
- Postdoctoral researchers in neurodegeneration laboratories
Continuing Education
NYU Langone hosts conferences and seminars on neurodegenerative diseases:
- Annual Alzheimer's disease symposium
- Parkinson's disease research day
- Neuroimaging workshops
International Collaborations
NYU Langone maintains extensive international collaborations:
Major Partnerships
- University College London: Joint research on tau pathology
- University of Cambridge: Biomarker development collaboration
- Karolinska Institute: Parkinson's disease research
- Japanese Institutions: Multiple collaborations in neurodegeneration research
Global Research Networks
NYU Langone participates in international research consortia:
- Alzheimer's Disease International
- International Parkinson's and Movement Disorders Society
- Lewy Body Dementia Association
Research Infrastructure
Core Facilities
NYU Langone provides access to state-of-the-art research infrastructure:
- Neuroimaging Center: 3T and 7T MRI, PET/CT, cyclotron
- Biomarker Core: CSF and blood biomarker analysis
- Genomics Core: Genetic sequencing and analysis
- Animal Facility: Transgenic models of neurodegeneration
Biobanking
The institution maintains important research resources:
- Brain bank with well-characterized specimens
- CSF and plasma sample collections
- DNA and RNA resources
- Clinical data repository
Funding and Support
Federal Funding
NYU Langone neurodegeneration research is supported by:
- National Institute on Aging (NIA): Alzheimer's disease research
- National Institute of Neurological Disorders and Stroke (NINDS): Parkinson's disease and other disorders
- National Institute of Mental Health (NIMH): Related conditions
Foundation Support
- Alzheimer's Association: Research grants and training
- Michael J. Fox Foundation: Parkinson's disease research
- Lewy Body Dementia Association: LBD research
Industry Partnerships
Active pharmaceutical partnerships support clinical development.
Future Directions
Strategic Priorities
Precision Medicine
- Biomarker-driven patient stratification
- Genetic subtyping of neurodegenerative diseases
- Individualized treatment approaches
Early Intervention
- Preclinical disease detection
- Preventive interventions
- Risk factor modification
Novel Therapeutics
- Small molecule disease-modifying agents
- Antibody-based therapies
- Gene therapy approaches
Emerging Technologies
- Advanced AI for diagnosis and monitoring
- Digital health platforms
- Novel drug delivery systems
Impact on Neurodegeneration Field
Scientific Contributions
NYU Langone researchers have made significant contributions to:
- Early detection and prevention strategies
- Biomarker development and validation
- Clinical trial design and conduct
- Understanding of Lewy body dementia
Clinical Care
The institution provides exceptional care for patients with neurodegenerative diseases, integrating research with clinical practice.
Training
NYU Langone has trained numerous researchers and clinicians who now lead neurodegenerative disease programs worldwide.
Cross-Links
Related pages in NeuroWiki:
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Tau](/proteins/tau)
- [Amyloid-Beta](/proteins/amyloid-beta)
- [Biomarkers](/research/biomarkers)
Biomarker Development
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
- [Neurodegeneration Research](/research/neurodegeneration)
Fluid Biomarkers:
- [Development and validation of plasma p-tau assays](/proteins/tau)
- [CSF biomarker profiles for early detection](/events/aaic-2026/early-detection)
- [Novel marker discovery using proteomics and metabolomics](/technologies/proteomics)
- [Biomarker validation in diverse populations[@howell2023]](/genes/ar)
- [NYU Langone Health](https://nyulangone.org)
- [NYU Langone Neurology](https://nyulangone.org/care/neurology)
- [NYU ADRC](https://nyulangone.org/research/alzheimers-disease-research-center)
- [Center for Cognitive Neurology](https://nyulangone.org/locations/centers/center-cognitive-neurology)
- [PubMed - NYU Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=NYU+Langone+neurodegeneration)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[NYU Langone Annual Report 2025 (2025)](https://nyulangone.org)
[Reich SG et al, Parkinson disease clinical care (2019)](https://pubmed.ncbi.nlm.nih.gov/31171447/)
[Lipton RB et al, Dementia with Lewy bodies (2020)](https://pubmed.ncbi.nlm.nih.gov/32246844/)
[Sano M et al, Alzheimer disease clinical trials at NYU (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)
[GPCR drug discovery in CNS disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Dopamine receptor dysfunction in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Adenosine A2A receptor as therapeutic target in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Structure-based drug design for GPCRs (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[GPCR structure and function in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35672345/)
[GPCR drug discovery in CNS disorders: emerging opportunities (2022)](https://pubmed.ncbi.nlm.nih.gov/36451922/)
[Non-Motor Diagnostic Criteria in Huntington Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38094638/)
[Huntington's Disease Clinical Trials Corner: March 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38489195/)
[Quality of life in Huntington disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36084356/)
[Cognitive change trajectories in Huntington disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36994811/)
[Non-Motor Phenotype of Huntington Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37199368/)
[Huntington's disease biomarker development (2023)](https://pubmed.ncbi.nlm.nih.gov/37565221/)
[ASO gene silencing therapies for Huntington's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39024687/)
[Huntington's disease: advances in molecular therapies (2024)](https://pubmed.ncbi.nlm.nih.gov/39024688/)
[Mitochondrial dysfunction in Alzheimer's disease: new insights (2020)](https://pubmed.ncbi.nlm.nih.gov/32022787/)
[Mitochondrial dysfunction in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36098900/)
[Alpha-synuclein and mitochondrial dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/36454906/)
[LRRK2 and mitochondrial function in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36597060/)
[Mitophagy in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37353678/)
[Mitophagy and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37549832/)
[Mitochondria-targeted therapeutics in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37762508/)